CN119790064A - Il2变体和包括该il2变体的蛋白复合体 - Google Patents

Il2变体和包括该il2变体的蛋白复合体 Download PDF

Info

Publication number
CN119790064A
CN119790064A CN202380061464.0A CN202380061464A CN119790064A CN 119790064 A CN119790064 A CN 119790064A CN 202380061464 A CN202380061464 A CN 202380061464A CN 119790064 A CN119790064 A CN 119790064A
Authority
CN
China
Prior art keywords
variant
antibody
protein complex
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380061464.0A
Other languages
English (en)
Chinese (zh)
Inventor
房孝住
郑容峻
郑圣烨
朴永振
姜锡瓒
朴范
朴庠炫
赵善贞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Master Biology Co ltd
Original Assignee
Master Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Master Biology Co ltd filed Critical Master Biology Co ltd
Publication of CN119790064A publication Critical patent/CN119790064A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202380061464.0A 2022-08-23 2023-08-21 Il2变体和包括该il2变体的蛋白复合体 Pending CN119790064A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20220105643 2022-08-23
KR10-2022-0105643 2022-08-23
KR20230057361 2023-05-02
KR10-2023-0057361 2023-05-02
PCT/KR2023/012348 WO2024043643A1 (ko) 2022-08-23 2023-08-21 Il2 변이체 및 이를 포함하는 단백질 복합체

Publications (1)

Publication Number Publication Date
CN119790064A true CN119790064A (zh) 2025-04-08

Family

ID=90013668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380061464.0A Pending CN119790064A (zh) 2022-08-23 2023-08-21 Il2变体和包括该il2变体的蛋白复合体

Country Status (6)

Country Link
EP (1) EP4578871A1 (enExample)
JP (1) JP2025527694A (enExample)
KR (1) KR102655850B1 (enExample)
CN (1) CN119790064A (enExample)
AU (1) AU2023330441A1 (enExample)
WO (1) WO2024043643A1 (enExample)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
DK3186283T3 (da) * 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
AU2017213659B2 (en) * 2016-02-05 2024-04-18 Washington University Compositions and methods for targeted cytokine delivery
AU2017335771A1 (en) * 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3504234A4 (en) * 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
MY201482A (en) * 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
IL275426B2 (en) * 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
JP2022554141A (ja) 2019-10-25 2022-12-28 オーデンツ セラピューティクス，インコーポレーテッド 糖原病を治療するための組成物及び方法
KR102559355B1 (ko) * 2020-01-31 2023-07-25 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
CN118271419A (zh) * 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
US20240034854A1 (en) 2020-08-26 2024-02-01 Reventas Limited Improvements In Or Relating To Plastic Recycling

Also Published As

Publication number Publication date
JP2025527694A (ja) 2025-08-22
KR20240028310A (ko) 2024-03-05
AU2023330441A1 (en) 2025-02-20
WO2024043643A1 (ko) 2024-02-29
EP4578871A1 (en) 2025-07-02
KR102655850B1 (ko) 2024-04-11

Similar Documents

Publication Publication Date Title
AU2018393424B2 (en) Triabody, preparation method and use thereof
CN108350076B (zh) 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
TWI564306B (zh) 雙特異性抗體
JP2025020138A (ja) 免疫細胞活性化のための二重特異性抗体
JP2019106997A (ja) 抗腫瘍活性を有する新規な二重特異的結合分子
JP2021526509A (ja) 抗ｃｄ２４組成物及びその使用
WO2019196522A1 (zh) 抗体及抗体改造方法
CN112119094B (zh) 与淋巴细胞活化基因3特异性结合的单克隆抗体及其用途
WO2020103885A1 (en) Anti-pd-1 antibodies and uses thereof
JP2021512884A (ja) 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ−４抗体
JP2022538375A (ja) Ｐｄ－１と結合する抗体
KR20200124701A (ko) 항―ｐｄ－１ 항체 및 그의 용도
JP7812988B2 (ja) Ｌｅｗｉｓ Ｙに対するヒト化抗体
TW202309083A (zh) 抗ｃｌｄｎ４－抗ｃｄ１３７雙特異性抗體
CA3246716A1 (en) ANTI-HER2/TROP2 ANTIBODIES AND THEIR USES
CN119790064A (zh) Il2变体和包括该il2变体的蛋白复合体
EP4159765A1 (en) Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor
US20250074999A1 (en) Antibodies against lypd3
RU2818312C9 (ru) Биспецифическое антитело или его антигенсвязывающий фрагмент и способ их получения
RU2818312C1 (ru) Биспецифическое антитело или его антигенсвязывающий фрагмент и способ их получения
KR20130057959A (ko) 항 ｈｅｒ2 단일클론항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
KR20140025836A (ko) 항 ＨＥＲ2/Ｎｅｕ 단일클론항체와 ＩＬ-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물
EP4682170A1 (en) Novel cd3-binding antibody and multispecific antibody comprising same
KR20230035508A (ko) B7-H3 및 TGFβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도
WO2025132836A1 (en) Antibodies against cd24

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination